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Serum levels of the soluble epidermal growth factor receptor (sEGFR) and its ligands epidermal growth factor (EGF), transforming
growth factor-a (TGF-a) and amphiregulin (AR) were measured in healthy donors and patients with non-small cell lung cancer
(NSCLC) and head and neck carcinoma (HNC). In NSCLC, we found sEGFR and EGF levels significantly lowered in patients with
respect to healthy donors. In HNC patients, significantly diminished levels were found in the case of sEGFR, EGF and also AR. In both
malignancies, no significant association was found between the serum levels of the molecules and the patients’ gender, age or smoking
habit. Only a significant association was found between the decrease of sEGFR and the absence of distant metastasis in NSCLC and
the tumour stage in HNC. The most interesting result was that combining sEGFR and EGF, sensitivities of 88% in NSCLC and 100%
in HNC were reached without losing specificity (97.8% in both cases). The use of discriminant analysis and logistic regression
improved the sensitivity for NSCLC and the specificity for HNC. These data demonstrate a potentially interesting value of the serum
levels of sEGFR and EGF, especially when combined, as markers for NSCLC and HNC.
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The epidermal growth factor receptor (EGFR, also known as HER1
or ErbB1) is a member of the HER family of membrane receptors.
It is expressed on the surface of epithelial cells and presents an
intracellular tyrosine kinase (TK) activity and one extracellular
domain (termed as soluble epidermal growth factor receptor
(sEGFR)) that can be shed and released into the bloodstream
(Baron et al, 2003). The specific ligands for the EGFR are the
epidermal growth factor (EGF), transforming growth factor-a
(TGF-a) and amphiregulin (AR), although it can also bind
betacellulin and epiregulin, which are also ligands for HER4
(Casalini et al, 2004).
Analysis of tumour levels of the EGFR as assayed by
immunohistochemistry or in tumour lysates has shown that its
overexpression is correlated with disease progression, poor
survival and development of resistance to cytotoxic agents, being
involved in over 70% of all cancers (Baselga, 2002; Jimeno and
Hidalgo, 2005), specially in non-small cell lung cancer (NSCLC)
and head and neck carcinoma (HNC). Recently, tumours that
overexpress the EGFR have been challenged with the anti-
EGFR therapies currently approved (Jimeno and Hidalgo, 2005;
Mendelsohn and Baselga, 2006).
In addition to the traditional tissue-based analysis, there is an
evident interest on the evaluation of the serum levels of the EGFR
and its ligands, not only because they could indicate the presence
of the malignancy but for their potential utility in the follow-up of
patients, especially those receiving anti-EGFR therapies. Unfortu-
nately, the number of publications that have analysed the levels of
the receptor in human serum or plasma samples is rather small.
Some of these studies dealt with squamous cell cancer of the head
and neck (Hoffmann et al, 2001; Gokhale et al, 2005), thymoma
(Sasaki et al, 2004), ovarian (Baron et al, 2003) and lung cancer
(Sasaki et al, 2003), but comparison of the published data reveals a
great disparity. On the other hand, studies evaluating the levels of
the ligands in serum are very scarce and we have not found any
study evaluating the levels of EGFR and their ligands in the same
set of individuals.
Thus, considering this study as a first step to further explore
the utility of these molecules as tumour markers, we aimed to
determine the levels of sEGFR and their ligands in the serum of
healthy donors and compare them with the levels in patients of
NSCLC and HNC. We also evaluated if there was any correlation
between the serum levels of the receptor and the cytokines and the
clinicopathological features of the patients. Our data show that the
levels of serum sEGFR, EGF, TGF-a and AR are altered in patients
of both NSCLC and HNC. Moreover, these serum levels could have
a potential clinical value in the detection/management of both
diseases.
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Subjects
Serum samples from 25 patients with NSCLC and 50 patients with
HNC were collected at the hospitals ‘CHUVI’ (Complexo
Hospitalario Universitario de Vigo) and ‘POVISA’ in Vigo (Spain).
Hospital records and pathology slides were revised and TNM
staging was made according to the 2002 UICC classification (Sobin
and Wittekind, 2002). Informed consent was obtained from
participants before entering the study and only cancer patients
with untreated disease were included. The mean age (7s.d.) of the
patients was 62714 years (median: 61; range: 37–82) for NSCLC
and 61710 years (median: 60; range: 42–91) for HNC. Sera from
51 healthy donors were provided by ‘Centro de Transfusio ´nd e
Galicia’ (Spain). The number of samples evaluated for each of the
molecules included in this study is shown in the Supplementary
Table 1.
Determination of serum sEGFR, EGF, TGF-a and AR levels
Serum samples from controls and patients were obtained by
venipuncture and blood clotting as described before (Cordero
et al, 2000) and assayed by ELISA tests. Serum levels of sEGFR
were measured with the EGFR Duoset
s kit (DY231; R&D Systems,
Minneapolis, MN, USA); EGF levels with the Quantikine
s EGF kit
(DEG00, R&D Systems); TGF-a levels with the Quantikine
s TGF-a
kit (DTGA00, R&D Systems) and AR levels with the AR Duoset
s
kit, (DY262, R&D Systems). For all the evaluated molecules, the
method was based on the addition of diluted serum samples
and standards to microtiter wells (Costar, Corning, NY, USA),
precoated with a specific capture antibody. After incubation at
room temperature, a conjugated detector antibody and a
chromogenic solution were added and the reaction was stopped.
Colorimetric quantification was performed with a microplate
reader (550; Bio-Rad, Hercules, CA, USA) using dual readings
at 450/570nm. Protein concentrations were determined from
the standard curves obtained according to the manufacturer’s
protocol.
The reproducibility of each commercial kit employed in this
work was found to be coincident with the values provided by the
manufacturer.
Statistical methods
All the statistical tests were performed with the SPSS software
package (release 14.0). The normal distribution of the variables
was assessed by the non-parametric Kolmogorov–Smirnov test
and the homogeneity of variances was evaluated using Levene’s
test. Although many of the variables studied presented a normal
distribution and homogeneous variances, non-parametric tests
were used since the number of samples tested was lower than 30
individuals for some of the groups analysed (see Supplementary
Table 1). Correlations between variables were assessed by
Spearman’s rank-correlation coefficient and differences between
groups compared with the Mann–Whitney’s U test. An abnormal
elevation of the serum levels of the molecules was defined as any
value above the mean value for the healthy group plus two
standard deviations and an abnormal reduction as any value below
the mean value for the control group minus two standard
deviations. These abnormal values were considered as positive
for the marker in consideration. Receiver operating characteristics
curves (ROCs) were constructed as plots of the percentage of true-
positives (sensitivity) against the percentage of false-positives
(100-specificity), to calculate the area under each curve (Cordero
et al, 2000). Differences in positivity were compared with the
clinicopathologic characteristics using the analysis of variance
(Ayude et al, 2003–2004). All the statistical tests were two-sided
and a P-value smaller than 0.05 was considered as statistically
significant.
To increase the information obtained from the four molecules
tested (sEGFR, EGF, TGF-a and AR), the sensitivity values
previously calculated for each of them were combined, considering
those values as the number of true-positives in the test. Similarly,
specificity values were used as the number of false-positives
detected by the molecules.
We also applied the discriminant analysis (DA), which attempts
to find one or more linear combinations of independent variables
to get the better separation of different groups of cases, to evaluate
the utility of the different combinations of the four molecules for
the discrimination between donors and patients. Besides, we tried
the logistic regression (LR) where each marker is also included as a
linear term in an equation. Once probabilities of having cancer
were estimated, by DA and LR, we generated ROC curves to predict
the existence of cancer from the positivity of multiple markers.
RESULTS
Serum levels of sEGFR and its ligands in healthy and
NSCLC patients
Serum levels of sEGFR, EGF, TGF-a and AR in NSCLC patients
were compared with the levels in healthy donors and results are
Table 1 Serum levels of sEGFR, EGF, TGF-a and AR in NSCLC patients compared with levels in healthy donors
Serum n M7s.d. Me Range Mann–Whitney U-test
sEGFR
(ngml
 1) Donors 50 35.975.2 36.4 20.6–44.2
NSCLC 25 25.574.5 25.3 19.4–40.1 Po0.0001
EGF
(pgml
 1) Donors 45 917.47245.9 946.7 382.3–1671.0
NSCLC 25 294.37298.2 196.6 0.0–952.4 Po0.0001
TGF-a
(pgml
 1) Donors 44 6.074.2 6.2 0.0–14.5
NSCLC 25 9.2712.3 4.3 0.0–45.9 NS
AR
(pgml
 1) Donors 45 19.6717.4 15.4 0.0–85.8
NSCLC 24 17.2719.4 14.6 0.0–74.8 NS
AR¼amphiregulin; EGF¼epidermal growth factor; NSCLC¼non-small cell lung cancer; sEGFR¼soluble epidermal growth factor receptor; TGF¼transforming growth factor;
M7s.d.¼mean7standard deviation; Me¼median; n¼number of samples; NS¼nonsignificant.
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sshown in Table 1. In the healthy population, used as control group,
the serum levels of sEGFR, EGF, TGF-a and AR were found to
fit a normal distribution. The mean level of sEGFR was
35.975.2ngml
 1. Levels of the specific EGFR ligands were lower
than those obtained for the receptor: the mean value for the
circulating EGF was 917.47245.9pgml
 1, whereas TGF-a showed
an average of 6.074.2pgml
 1 and AR presented a mean value of
19.6717.4pgml
 1. The levels of the four molecules were not
correlated in donors as found by the non-parametric Spearman’s
rank-correlation coefficient.
When the serum levels of sEGFR were analysed in NSCLC
patients (Table 1), we found a mean of 25.574.5ngml
 1. These
levels were significantly decreased (Po0.0001) when compared
with those of the control group (Figure 1A). Considering a cutoff
value of 25.5ngml
 1 (mean value of the healthy group  2s.d.) for
sEGFR positivity, decreased serum sEGFR levels were observed
in 15 out of 25 NSCLC patients and in one out of 50 donors,
representing a 60% sensitivity with a 98% specificity. The area
under the ROC curve (data not shown) was 0.925 (Po0.0001).
In the case of serum EGF (Figure 1B and Table 1), its average
levels were 294.37298.2pgml
 1, significantly lower than those of
controls (Po0.0001) although they presented a higher dispersion
of values. Decreased EGF was found in 72% (18 out of 25) of the
patients with a 97.8% specificity (1 out of 45 donors was detected
as positive for cancer), when the mean value of the healthy group
minus two standard deviations (425.6pgml
 1) was used as the
cutoff point. The area under the ROC curve (data not shown) was
0.940 (Po0.0001), higher than the one obtained for sEGFR.
For TGF-a (Figure 1C and Table 1), though not statistically
significant, the mean levels (9.2712.3pgml
 1) were higher in
patients than in controls. However, the median, (4.3pgml
 1,
range: 0–45.9) was lower because of the number of non-detected
(ND) values (Supplementary Figure 1). For a cutoff value of
14.4pgml
 1 (mean of the healthy group plus two standard
deviations), positivity was observed in six out of 25 NSCLC
patients (20.0%), with a 97.7% specificity (one out of 44 donors).
Regarding AR (Figure 1D and Table 1), an average of
17.2719.4pgml
 1 was found, not showing significant differences
with respect to control values. In this case, we considered the lower
limit of AR levels (0.0pgml
 1) as a cutoff point value. ND values
were observed in six out of 24 NSCLC patients (25.0%) with a
95.6% specificity (two out of 45 donors).
The levels of the molecules studied did not show statistical
correlation in NSCLC patients.
Relationship between the serum levels of sEGFR and its
ligands, and the clinicopathological features in NSCLC
patients
No significant association was found between the serum protein
levels of each of the molecules evaluated and patients’ gender, age,
smoking habits or the tumour pathological subtype and stage
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Figure 1 Representation of (A) sEGFR levels (ngml
 1) in sera from 50 healthy donors, 25 patients with NSCLC and 50 HNC patients; (B) EGF levels
(pgml
 1) in sera from 45 healthy donors, 25 patients with NSCLC and 41 HNC patients; (C) TGF-a levels (pgml
 1) in sera from 44 healthy donors, 25
patients with NSCLC and 34 HNC patients; (D) AR levels (pgml
 1) in sera from 45 healthy donors, 24 patients with NSCLC and 25 HNC patients. Values
of sEGFR and its ligands followed a normal distribution. The continuous blue line represents the mean of the control group, whereas the dashed blue line
shows the lower normal limit (mean 2s.d. of the control group) for sEGFR, EGF and AR and the upper normal limit (meanþ2s.d. of the control group) for
TGF-a.
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Characteristics sEGFR mean (ngml
 1) ANOVA P Positive cases EGF mean (pgml
 1) ANOVA P Positive cases
Gender 0.639 0.568
Female 24.5 3/5 (60.0%) 398.3 3/5 (60.0%)
Male 25.5 10/17 (58.8%) 307.8 12/17 (70.6%)
Age 0.108 0.695
p60 26.7 4/11 (36.4%) 354.5 7/11 (63.6%)
460 23.8 9/11 (81.8%) 302.2 8/11 (72.7%)
Smoking habits 0.746 0.786
Non-smoker 24.1 2/4 (50.0%) 417.6 3/4 (75.0%)
Smoker 25.7 10/17 (58.8%) 303.2 11/17 (64.7%)
Ex-smoker 23.6 1/1 (100%) 400.0 1/1 (100%)
Pathological subtype 0.278 0.129
Adenocarcinoma 24.7 4/7 (57.1%) 300.6 5/7 (71.4%)
Epidermic 23.0 5/6 (83.3%) 237.2 5/6 (83.3%)
Large cell 21.1 1/1 (100%) 952.4 0/1 (0.0%)
Unclassified NSCLC 28.1 3/8 (37.5%) 343.1 5/8 (62.5%)
Distant metastasis 0.040 0.702
M0 21.5 4/4 (100%) 382.5 3/4 (75.0%)
M1 26.1 9/18 (50.0%) 316.3 12/18 (66.7%)
Stage 0.128 0.779
IIIa 21.5 2/2 (100%) 476.2 1/2 (50.0%)
IIIb 21.5 2/2 (100%) 288.8 2/2 (100%)
IV 26.1 9/18 (50.0%) 316.3 12/18 (66.7%)
ANOVA¼analysis of variance; EGF¼epidermal growth factor; NSCLC¼non-small cell lung cancer; sEGFR¼soluble epidermal growth factor receptor. P-values were
calculated using one-way ANOVA. P-values o0.05 were considered significant. Positivity was defined as any value below the mean value of the donor group 2s.d. The
pathological subtype named as ‘Unclassified NSCLC’ was not included in the statistical analysis. For each condition, the significance of the values was studied within the patient
cohort.
Table 3 Serum values of the TGF-a and the AR in NSCLC according to the clinicopathological features
Characteristics TGF-a mean (pgml
 1) ANOVA P Positive cases AR mean (pgml
 1) ANOVA P Positive cases
Gender 0.281 0.783
Female 14.6 2/5 (40.0%) 20.4 2/5 (40.0%)
Male 7.6 3/17 (17.6%) 17.5 3/17 (17.6%)
Age 0.382 0.630
p60 11.6 3/11 (27.3%) 20.3 2/11 (18.2%)
460 6.8 2/11 (18.2%) 16.0 3/11 (27.3%)
Smoking habits 0.709 0.313
Non-smoker 11.9 2/4 (50.0%) 30.2 1/4 (25.0%)
Smoker 9.1 3/17 (17.6%) 16.4 3/17 (17.6%)
Ex-smoker 0.0 0/1 (0.0%) 0.0 1/1 (100%)
Pathological subtype 0.402 0.452
Adenocarcinoma 11.8 2/7 (28.6%) 27.1 2/7 (28.6%)
Epidermic 3.4 0/6 (0.0%) 10.4 1/6 (16.7%)
Large cell 0.0 0/1 (0.0%) 13.3 0/1 (0.0%)
Unclassified NSCLC 12.4 3/8 (37.5%) 16.7 2/8 (25.0%)
Distant metastasis 0.271 0.242
M0 2.9 0/4 (0.0%) 7.4 1/4 (25.0%)
M1 10.6 5/18 (27.8%) 20.5 4/18 (22.2%)
Stage 0.550 0.513
IIIa 2.2 0/2 (0.0%) 6.8 0/2 (0.0%)
IIIb 3.7 0/2 (0.0%) 8.0 1/2 (50.0%)
IV 10.6 5/18 (27.8%) 20.5 4/18 (22.2%)
ANOVA¼analysis of variance; AR¼amphiregulin; NSCLC¼non-small cell lung cancer; TGF¼transforming growth factor. P-values were calculated using one-way ANOVA.
P-values o0.05 were considered significant. Positivity was defined as any value above (for TGF-a) or below (for AR) the mean value of the donor group+(for TGF-a)o r (for
AR) 2s.d. The pathological subtype named as ‘‘Unclassified NSCLC’’ was not included in the statistical analysis. For each condition, the significance of the values was studied within
the patient cohort.
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significantly (P¼0.040) associated with decreased levels of sEGFR
(Table 2) and 100% of the patients without distant metastasis were
positive for the sEGFR.
Combined use of sEGFR, EGF, TGF-a and AR serum levels
for NSCLC detection
The lack of correlation among the molecules analysed prompted us
to evaluate their performance when combining their cutoff points
to increase the sensitivity and/or the specificity of the test. Thirty-
eight donors and 24 NSCLC patients were included in this analysis
since their samples had been evaluated for the four molecules.
In Supplementary Table 2, we show these parameters for all the
combinations of measurements. Using the cutoff points mentioned
before, the combined use of sEGFR and EGF levels rendered the
best results, since sensitivity was increased to 88% maintaining a
high specificity (97.8%).
An alternative method to distinguish between donors and
patients is to use the DA. The best results were obtained combining
sEGFR, EGF and TGF-a levels, which allowed the correct
classification of 90.2% of the healthy individuals and 100% of
the NSCLC patients. A ROC curve was constructed for the
combination of those three molecules, showing an area under
the curve of 0.989 (Figure 2A). Interestingly, the combination of
sEGFR and EGF levels presented almost the same efficacy, with an
area under the corresponding ROC curve of 0.982 (data not
shown). The LR model using those three markers also yielded a
wide area under the ROC curve, with a value of 0.993 (Figure 2B),
correctly classifying 92.7% of the donors and 96% of the patients.
Serum levels of sEGFR and its ligands in HNC patients
Serum levels of sEGFR, EGF, TGF-a and AR in HNC patients were
compared with the levels in healthy donors, the results obtained
are shown in Table 4. Analysis of the sEGFR levels in HNC patients
showed a mean value of 21.276.2ngml
 1. When these values were
compared with those obtained for the donor group, we found
significant differences (Po0.0001) that were also revealed for the
comparison with the NSCLC group (P¼0.002) (Figure 1A). Using
25.5ngml
 1 as the cutoff value (set before for the sEGFR levels as
the mean–2s.d. in donors) positivity for the sEGFR was observed
in 40 out of the 50 HNC patients (80% sensitivity with 98%
specificity). The approximate area under the ROC curve (data not
shown) was 0.961 (Po0.0001).
EGF levels in HNC patients showed a mean of 230.37
204.2pgml
 1 (Table 4), also significantly lower (Po0.0001) than
those of controls (Figure 1B). Selecting a cutoff value of
425.6pgml
 1 (mean 2s.d. in donors) positivity of EGF was found
in 82.9% (34 out of 41) of the patients (specificity of 97.8%). The
area under the ROC curve built for EGF (data not shown) was
0.979 (Po0.0001).
The mean TGF-a value in HNC was 20.5748.6pgml
 1 (Table 4
and Figure 1C). As in NSCLC, a trend to increased TGF-a levels
was observed in HNC (Supplementary Figure 2) and nine out of
34 patients were positive (23.5% sensitivity with 97.7% specificity)
when setting a cutoff point of 14.4pgml
 1 (meanþ2s.d. in
donors). Finally, the mean AR value was 10.5713.3pgml
 1
(Table 4 and Figure 1D). In contrast with NSCLC, the difference
between donors and patients was statistically significant, defining a
cutoff value of 0.0pgml
 1, AR was undetectable and therefore
positive for the test in 13 out of 25 HNC patients (52% sensitivity
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Figure 2 ROCs for the combined levels of sEGFR, EGF and TGF-a when applied to the comparison of healthy donors and NSCLC patients by DA (A)
and LR (B) or to the comparison of donors and HNC patients by DA (C) and LR (D).
EGFR, EGF, TGF-a and AR in NCSLC and HNC
Y Lemos-Gonza ´lez et al
1573
British Journal of Cancer (2007) 96(10), 1569–1578 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
swith a 95.6% specificity). The area under the ROC curve for AR
levels (data not shown) was significant (P¼0.004), with a value of
0.706.
A weak but significant negative correlation between sEGFR and
AR, neither detected in NSCLC nor in donors, was demonstrated
for the HNC group (r¼ 0.419).
Relationship between the serum levels of sEGFR and its
ligands, and the clinicopathological features in HNC
patients
The study of the relationship between the serum levels of sEGFR
and EGF (Table 5) and TGF-a and AR (Table 6) and the
clinicopathological features of the patients demonstrated a
significant association between the decrease of sEGFR levels and
the tumour stage (P¼0.011). We also found an association
between decreased levels of sEGFR and the patients age that,
although significant (P¼0.005), could be related to the fact that
advanced stages correlated with older patients (data not shown).
Combined use of sEGFR EGF, TGF-a and AR serum levels
for HNC detection
As shown before, the serum levels of sEGFR or EGF alone are
acceptably informative about the existence of HNC. Nevertheless,
we tried the combination of the four molecules tested to enhance
the sensitivity of the tests (Supplementary Table 3). Interestingly,
just with the combination of sEGFR and EGF levels, we detected all
the 40 HNC patients (100% sensitivity) with 97.8% specificity. In
addition, the statistical tests applied with the same three molecules
used for NSCLC (sEGFR, EGF and TGF-a) allowed a correct
discrimination of 97.6% of the healthy donors and 100% of the
HNC patients by DA and 100% of the healthy donors and 100% of
the HNC patients by LR. In fact, a wide area under the ROC curve,
with a value of 1.000 (Po0.0001), was obtained by both DA and LR
(Figure 2C and D), although just with the combination of sEGFR
and EGF the area under the ROC curve was 0.999 (Po0.0001) (data
not shown).
DISCUSSION
Novel serum markers are still needed in the case of malignancies
such as NSCLC and HNC, not only for diagnosis but also for
prognosis evaluation and follow-up of the patients. The EGFR is a
strong biomarker candidate for multiple reasons. First of all, it
is overexpressed in most of the tumours from NSCLC and HNC
patients. This overexpression, ultimately causing increased pro-
liferation or cell motility, and decreased apoptosis (Jimeno and
Hidalgo, 2005), has been related to the progression of the tumour.
Another appealing reason is the fact that new approved therapies
for those cancers are targeting EGFR, based on the inhibition of its
TK activity (Baselga, 2002; Jimeno and Hidalgo, 2005).
On the other hand, it is known that a portion of the membrane
receptor is shed into the bloodstream thus making plasma or
serum an excellent source, best than tumour tissues, to evaluate
dynamic variations of the EGFR since the diagnosis and during
treatment.
Moreover, it has been described that overexpression of the
receptor is often associated with an increased expression of its
ligands (Rubin Grandis et al, 1998). This and the evidence that the
combined use of several markers can improve the sensitivity and
specificity of the test (Ayude et al, 2003–2004; Lu et al, 2004;
Skates et al, 2004) prompted us to measure the levels of sEGFR
EGF, TGF-a and AR in the serum of healthy individuals and
patients with NSCLC or HNC. This work aimed first to establish an
average value for the control population, and then to study the
variations in patients, correlating the levels of the four molecules
with the classical clinicopathological conditions. Finally, to explore
the putative role of these proteins as tumour biomarkers, we
combined the values of the four molecules applying multivariate
analyses.
To our knowledge this is the first study where the serum levels
of EGFR and its ligands are measured in the same set of healthy
individuals, NSCLC patients and HNC patients. Previous reports
about the levels of sEGFR in healthy individuals showed discrepant
values, ranging from 4.5 to 159.1ngml
 1 (Choi et al, 1997;
Hoffmann et al, 2001; Markopoulos et al, 2001; Ramesh Kumar
et al, 2001; Carney et al, 2002; Baron et al, 2003; Kong et al, 2004;
Gokhale et al, 2005). Even using the same commercial ELISA kit,
the differences are remarkable: 36.4ngml
 1, in our study, vs
74.8ngml
 1 reported by Baron et al (2001). EGF levels also
presented a wide range of variation in donors, from 71.9 to
490.5pgml
 1 (Baron et al, 1999; Efimova et al, 2005; Hashimoto
et al, 2005), all these values lower than the ones reported here.
Studies on TGF-a levels in healthy subjects reported ranges from
non-detectable levels to 56.2pgml
 1 (Tomiya and Fujiwara, 1996;
Chien et al, 1997; Shim et al, 1998; Choi et al, 1999; Harada et al,
1999; Efimova et al, 2005). On the other hand, there are no reports
on AR in serum of healthy populations. Therefore, comparison
between different populations should be carefully addressed.
In this study, sEGFR and EGF levels were significantly decreased
in serum of NSCLC and HNC patients, whereas there was no
difference in TGF-a and AR levels were significantly lower only in
Table 4 Serum levels of sEGFR, EGF, TGF-a and AR in HNC patients compared with levels in healthy donors
Serum n M7s.d. Me Range Mann–Whitney U-test
sEGFR (ngml
 1) Donors 50 35.975.2 36.4 20.6–44.2
HNC 50 21.276.2 20.5 4.5–36.0 Po0.0001
EGF (pgml
 1) Donors 45 917.47245.9 946.7 382.3–1671.0
HNC 41 230.37204.2 211.9 0.0–911.3 Po0.0001
TGF-a (pgml
 1) Donors 44 6.074.2 6.2 0.0–14.5
HNC 34 20.5748.6 8.4 0.0 – 280.0 NS
AR (pgml
 1) Donors 45 19.6717.4 15.4 0.0–85.8
HNC 25 10.5713.3 0.0 0.0–45.0 P¼0.008
AR¼amphiregulin; EGF¼epidermal growth factor; HNC¼head and neck carcinoma; sEGFR¼soluble epidermal growth factor receptor; TGF¼transforming growth factor;
n¼number of samples; M7s.d.¼mean7standard deviation; Me¼median; NS¼nonsignificant.
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sHNC patients. Studies reported to date about sEGFR levels in
NSCLC are controversial. For instance, Schneider et al (1999) did
not find any alteration of sEGFR levels in occupation-derived lung
cancer patients. However, decreased serum sEGFR has been
reported in 42% of lung cancer patients by other authors (Carney
et al, 2002). As those studies included patients with heterogeneous
types of lung cancer, it is difficult to compare them with the one
reported here, since only non-small cell cancer patients were
included. On the other hand, two studies on HNC, using different
commercial kits, have reported no differences in sEGFR serum
levels in squamous cell carcinoma (Hoffmann et al, 2001; Gokhale
et al, 2005), although our results demonstrated that sEGFR could
detect HNC patients with an 80% sensitivity. A decrease in sEGFR
serum levels has also been shown in breast, ovarian, colon, bladder
and prostate carcinoma (Carney et al, 2002). On the contrary, in
cervical (Oh et al, 2000), gastric (Choi et al, 1997) and pituitary
carcinomas (Kong et al, 2004), a significant increase of sEGFR has
been detected.
This is the first report on circulating EGF, measured by ELISA
in NSCLC and HNC. EGF concentrations were found lowered in
both malignancies, in agreement with previous data in serum
of thyroid carcinoma patients (Nedvı ´dkova ´ et al, 1992). However,
an increase of EGF was found in pancreatic (Meggiato et al,
1999) and papillary thyroid carcinoma (Konturek et al, 2005),
and no alterations were found in ovarian cancer (Baron
et al, 1999), suggesting that its biological function is tissue-
dependent.
TGF-a levels did not change significantly in NSCLC and HNC
but showed a trend to higher levels, consequent with reports
confirming increased serum TGF-a in ovarian (Chien et al, 1997),
Table 5 Serum values of the sEGFR and the EGF in HNC according to the clinicopathological features
Characteristics sEGFR mean (ngml
 1) ANOVA P Positive cases EGF mean (pgml
 1) ANOVA P Positive cases
Gender ——
Female — — — —
Male 21.2 40/50 (80.0%) 230.3 34/41 (82.9%)
Age 0.005 0.672
p60 23.5 19/26 (73.1%) 217.6 19/22 (86.4%)
460 18.7 21/24 (87.5%) 245.1 15/19 (78.9%)
Smoking habits 0.564 0.981
Non-smoker 18.7 2/2 (100%) 235.1 1/1 (100%)
Smoker 21.3 38/48 (79.2%) 230.2 33/40 (82.5%)
Tumor location 0.613 0.404
Larynx 21.7 20/26 (76.9%) 263.9 17/21 (81.0%)
Oropharynx 21.2 7/9 (77.8%) 196.7 8/10 (80.0%)
Hipopharynx 18.5 7/8 (87.5%) 233.5 4/5 (80.0%)
Oral cavity 22.4 5/5 (100%) 51.8 3/3 (100%)
Tumor status 0.081 0.201
T0 27.6 0/1 (0.0%) 375.5 1/1 (100%)
T1 23.4 10/14 (71.4%) 315.1 9/13 (69.2%)
T2 23.2 8/12 (66.7%) 158.4 9/9 (100%)
T3 19.5 7/8 (87.5%) 106.3 6/6 (100%)
T4 18.1 14/14 (100%) 243.0 8/11 (72.7%)
Tx 16.2 1/1 (100%) 235.1 1/1 (100%)
Nodal status 0.231 0.799
N0 22.9 18/25 (72.0%) 244.0 17/20 (85.0%)
N1 19.1 9/11 (81.8%) 174.5 6/7 (85.7%)
N2 20.0 11/12 (91.7%) 224.1 9/12 (75.0%)
N3 17.6 2/2 (100%) 326.2 2/2 (100%)
Distant metastasis 0.291 0.854
M0 21.6 34/43 (79.1%) 227.6 29/34 (85.3%)
Mx 18.9 6/7 (85.7%) 243.5 5/7 (71.4%)
Stage 0.011 0.707
I 24.5 7/11 (63.6%) 290.8 8/10 (80.0%)
II 24.7 2/4 (50.0%) 212.8 2/2 (100%)
III 22.7 9/12 (75.0%) 179.8 8/9 (88.9%)
IV 18.2 22/23 (95.7%) 224.6 16/20 (80.0%)
Differentiation 0.437 0.379
Good 22.2 6/6 (100%) 270.6 3/4 (75.0%)
Moderate 21.8 24/33 (72.7%) 254.6 20/26 (76.9%)
Poor 19.0 9/10 (90.0%) 150.6 10/10 (100%)
ANOVA¼analysis of variance; EGF¼epidermal growth factor; sEGFR¼soluble epidermal growth factor receptor; HNC¼head and neck carcinoma. P-values were calculated,
and positivity was defined, as in Table 2. Tumours that could not be clinically evaluated were classified as Tx and were not included in the statistical analysis. For each condition,
the significance of the values was studied within the patient cohort.
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shepatocellular (Tomiya and Fujiwara, 1996; Harada et al, 1999),
colorectal (Shim et al, 1998), gastric (Moskal et al, 1995; Choi et al,
1999) and breast cancer (Chakrabarty et al, 1994) as measured by
RIA. For AR, we found a significant decrease in HNC, whereas in
NSCLC patients only a trend to impairment was detected. To our
knowledge, there is only one report on serum AR and TGF-a in
advanced NSCLC (healthy donors not measured) studying the
relationship of their serum levels with the response of patients to
gefitinib (Ishikawa et al, 2005). In that work, AR and TGF-a levels
were detected with the same commercial antibodies used here and
were quite similar to the ones shown by us. Our data also agree
with their observation of a high-value dispersion. Interestingly,
those authors proposed that the value of AR correlates with the
distinct response of the patients to the drug (Ishikawa et al, 2005).
Therefore, further studies to establish if the serum levels of AR
during treatment are useful for predicting chemosensitivity of
patients, will be of great aid.
Interestingly, sEGFR levels in stage I HNC tumours are a great
deal lower than those in the healthy population, so as to support
further studies regarding early diagnosis (either alone or in
combination with other molecules). Because of the degree of
sample’s positivity and the dramatically altered levels, the same
comment applies to EGF. Unfortunately, in the case of NSCLC, we
could not confirm the correlation between early stages and lower
levels of sEGFR since in this type of cancer patients are usually
diagnosed in advanced stages.
For many cancers, up to date there is not a single diagnostic test
able to detect early-stage tumours. This also applies to prognosis in
spite of the easier management of tumours or biopsies in this case.
However, the number of potential molecular markers is constantly
increasing. For serum biomarkers, multivariate analysis is not
usually feasible because of the analysis of a single molecule at a
time. However, it has been recently demonstrated that combining
data from several markers by multivariate methods clearly
Table 6 Serum values of the TGF-a and the AR in HNC according to the clinicopathological features
Characteristics TGF-a mean (pgml
 1) ANOVA P Positive cases AR mean (pgml
 1) ANOVA P Positive cases
Gender ——
Female — — — —
Male 20.5 9/34 (26.5%) 10.5 13/25 (52.0%)
Age 0.287 0.643
p60 11.5 4/17 (23.5%) 9.1 7/12 (58.3%)
460 29.5 5/17 (29.4) 11.7 6/13 (46.2)
Smoking habits 0.826 0.016
Non-smoker 9.7 0/1 (0.0%) 41.0 0/1 (0.0%)
Smoker 20.8 9/33 (27.3%) 9.2 13/24 (54.2%)
Tumor location 0.360 0.089
Larynx 15.4 4/16 (25.0%) 6.7 10/17 (58.8%)
Oropharynx 13.5 3/9 (33.3%) 20.5 1/3 (33.3%)
Hipopharynx 58.3 1/5 (20.0%) 22.2 0/2 (0.0%)
Oral cavity 8.1 1/2 (50.0%) 0.0 1/1 (100%)
Tumor status 0.639 0.122
T0 11.3 0/1 (0.0%) 0.0 1/1 (100%)
T1 15.4 3/11 (27.3%) 14.0 3/7 (42.9%)
T2 12.9 3/8 (37.5%) 0.0 4/4 (100%)
T3 11.6 1/6 (16.7%) 20.3 0/3 (0.0%)
T4 47.8 2/7 (28.6%) 6.9 5/9 (55.6%)
Tx 9.7 0/1 (0.0%) 41.0 0/1 (0.0%)
Nodal status 0.581 0.115
N0 13.2 4/15 (26.7%) 10.5 6/12 (50.0%)
N1 12.6 1/6 (16.7%) 9.0 3/5 (60.0%)
N2 37.6 4/11 (36.4%) 7.0 4/7 (57.1%)
N3 4.9 0/2 (0.0%) 41.0 0/1 (0.0%)
Distant metastasis 0.837 0.052
M0 21.4 7/27 (25.9%) 8.6 13/22 (59.1%)
Mx 17.0 2/7 (28.6%) 24.3 0/3 (0.0%)
Stage 0.782 0.798
I 18.2 3/8 (37.5%) 13.4 3/6 (50.0%)
II 3.6 0/2 (0.0%) 0.0 1/1 (100%)
III 9.8 1/8 (12.5%) 12.2 2/5 (40.0%)
IV 29.1 5/16 (31.3%) 9.2 7/13 (53.8%)
Differentiation 0.778 0.250
Good 21.9 1/2 (50.0%) 0.0 4/4 (100%)
Moderate 24.6 7/23 (30.4%) 11.0 6/13 (46.2%)
Poor 9.8 1/8 (12.5%) 11.1 3/7 (42.9%)
ANOVA¼analysis of variance; AR¼amphiregulin; HNC¼head and neck carcinoma; TGF¼transforming growth factor. P-values were calculated, and positivity was defined, as
in Table 3. Tumours that could not be clinically evaluated were classified as Tx and were not included in the statistical analysis. For each condition, the significance of the values
was studied within the patient cohort.
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simproves the sensitivity and the specificity of the tests (Lu et al,
2004; Skates et al, 2004). Here, we studied four putative markers in
the same sera that allowed a multivariate analysis to detect the
independence of those factors in relation to cancer diagnosis.
An interesting result from our data is that combining sEGFR and
EGF, sensitivities of 88% in NSCLC and 100% in HNC are reached
without losing specificity (97.8% in both cases). The use of
statistical methods, such as DA and LR improved the sensitivity for
NSCLC. Thus, applying DA combining sEGFR, EGF and TGF-a,
90.2% of the healthy individuals and 100% of the NSCLC patients
were correctly classified. Regarding HNC, LR, on the combination
of sEGFR, EGF and TGF-a, correctly classified 100% of the healthy
donors and 100% of the HNC patients.
In conclusion, in this study we present a number of results
indicating the potential clinical utility of sEGFR, EGF, TGF-a and
AR in the management of NSCLC and HNC diseases. Further
studies are of interest to evaluate their use in diagnosis, prognosis
and disease therapy monitoring.
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